Faculty

Institution

Unit

Venue

Sarah Viall

Instructor of Molecular and Medical Genetics

Oregon Health & Science University

Affiliations

Division Of Genetics

Sarah Viall is currently serving as a Division Of Genetics Instructor of Molecular and Medical Genetics at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sarah Viall

Oregon Health & Science University

Instructor of Molecular and Medical Genetics

You can click a keyword to filter the displayed items

genetics diagnosis fabry disease health sciences biomarkers genetic epidemiology molecular genetics early diagnosis genetic disorders public health biostatistics genomics population health population genetics metabolism molecular diagnostics obstetrics and gynaecology biomarker (medicine) medical genetics developmental anomalies treatment development neonatology biomarker discovery disease detection early detection prenatal diagnosis prenatal testing disease diagnosis second-tier biomarker population-based screening nbs expansion study uncertain significance treated patients follow up pompe disease gaucher disease obesity medicine developmental system laboratory investigation translational research genetic variation clinical nutrition molecular psychiatry human genetics diabetes research pathology biochemistry translational medicine genome biology human biology medicine clinical lipidology quantitative genetics plo biology clinical biochemistry fungal genetics obesity genetic engineering statistical genetics cell metabolism forensic genetics individualized medicine muscular dystrophies genetic recombination heredity neurogenetics metabolic syndrome biology mammalian biology molecular metabolism molecular neurodegeneration nutritional biochemistry mutagenesis (molecular biology technique) behavioural genetics systems biology pediatric diabetes molecular biology metabolic pathways molecular medicine

Notable Scholarly Works

Notable Federal Grants

Collaborators

Simd 2026 Newborn Screening Position Statement - Points to Consider in Changing Landscapes of Newborn Screening. Molecular Genetics and Metabolism (2026)

Five Years of Newborn Screening for Pompe, Mucopolysaccharidosis Type I, Gaucher, and Fabry Diseases in Oregon. Molecular Genetics and Metabolism Reports (2025)

Embracing Use of Telemedicine in Metabolic Newborn Screening (Nbs) Follow-Up. Molecular Genetics and Metabolism (2023)

Newborn Screening for Fabry Disease in Oregon: Approaching the Iceberg of A143T and Variants of Uncertain Significance. American Journal of Medical Genetics Part C Seminars in Medical Genetics (2022)

biostatisticspediatricsuncertain significancegenetic disordersfabry diseasediagnosisdevelopmental anomaliesgenetic epidemiologygenetics

Population-Based Screening of Newborns: Findings From the Nbs Expansion Study (Part One). Frontiers in Genetics (2022)

Amy BrowerKee ChanMarc WilliamsSusan BerryRobert CurrierPiero RinaldoMichele CagganaAmy GaviglioWilliam WilcoxRobert SteinerIngrid A. HolmJennifer TaylorJoseph J. OrsiniLuca BrunelliJoanne AdelbergOlaf BodamerSarah ViallCurt ScharfeMelissa WassersteinJin Y. ChenMaria EscolarAaron GoldenbergKathryn SwobodaCan FiciciogluDieter MaternRachel LeeMichael Watson

public healthpopulation geneticspopulation-based screeninggenomicspopulation healthnbs expansion studygenetic epidemiologymedical geneticshealth sciencesgenetics

Oregon's Experience With Newborn Screening for Fabry Disease, Gaucher Disease, Pompe Disease and Mucopolysaccharidosis Type I. Molecular Genetics and Metabolism (2021)

pediatricsfabry diseasepompe diseasediagnosisprenatal diagnosisdisease diagnosisclinical epidemiologygaucher diseasemedicineprenatal testingobstetrics and gynaecology

The Role of Biomarkers for the Follow Up of Infants With Positive Newborn Screening Results for Fabry Disease. Molecular Genetics and Metabolism (2021)

Gisele PinoApril StudinskiAmy WhiteDawn PeckSara MinnichRandi GadeaMeghan StrenkJennifer GannonBryce HeeseEsperanza Font-MontgomeryAustin HammAnna DennisSarah ViallDimitar GavrilovSilvia TortorelliDevin OglesbeePiero RinaldoDietrich MaternKimiyo Raymond

biomarker discoverymetabolismgenetic disordersdisease detectionearly diagnosisfabry diseasefollow updiagnosisearly detectionmolecular geneticsmolecular diagnosticsbiomarkersgenetics

How a Baby With Classic Galactosemia Was Nearly Missed: When the Test Succeeds but System Fails. American Journal of Medical Genetics Part A (2020)

Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. International Journal of Neonatal Screening (2020)

Dawn S. PeckJean M. LaceyAmy L. WhiteGisele PinoApril L. StudinskiRachel FisherAyesha AhmadLinda SpencerSarah ViallNatalie ShallowAmy SiemonJ. Austin HammBrianna K. MurrayKelly L. JonesDimitar GavrilovDevin OglesbeeKimiyo RaymondDietrich MaternPiero RinaldoSilvia Tortorelli

early diagnosisbiomarkershealth sciencesbiomarker (medicine)second-tier biomarker

Mucopolysaccharidosis Type I Newborn Screening: Importance of Second Tier Testing for Ethnically Diverse Populations. American Journal of Medical Genetics Part A (2020)

1
2
10 / page

Sarah Viall

Instructor of Molecular and Medical Genetics

Oregon Health & Science University

Affiliations

Division Of Genetics

Sarah Viall is currently serving as a Division Of Genetics Instructor of Molecular and Medical Genetics at Oregon Health & Science University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Sarah Viall

Oregon Health & Science University

Instructor of Molecular and Medical Genetics

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Simd 2026 Newborn Screening Position Statement - Points to Consider in Changing Landscapes of Newborn Screening. Molecular Genetics and Metabolism (2026)

Five Years of Newborn Screening for Pompe, Mucopolysaccharidosis Type I, Gaucher, and Fabry Diseases in Oregon. Molecular Genetics and Metabolism Reports (2025)

Embracing Use of Telemedicine in Metabolic Newborn Screening (Nbs) Follow-Up. Molecular Genetics and Metabolism (2023)

biostatisticspediatricsuncertain significancegenetic disordersfabry diseasediagnosisdevelopmental anomaliesgenetic epidemiologygenetics

Population-Based Screening of Newborns: Findings From the Nbs Expansion Study (Part One). Frontiers in Genetics (2022)

public healthpopulation geneticspopulation-based screeninggenomicspopulation healthnbs expansion studygenetic epidemiologymedical geneticshealth sciencesgenetics

Oregon's Experience With Newborn Screening for Fabry Disease, Gaucher Disease, Pompe Disease and Mucopolysaccharidosis Type I. Molecular Genetics and Metabolism (2021)

pediatricsfabry diseasepompe diseasediagnosisprenatal diagnosisdisease diagnosisclinical epidemiologygaucher diseasemedicineprenatal testingobstetrics and gynaecology

The Role of Biomarkers for the Follow Up of Infants With Positive Newborn Screening Results for Fabry Disease. Molecular Genetics and Metabolism (2021)

biomarker discoverymetabolismgenetic disordersdisease detectionearly diagnosisfabry diseasefollow updiagnosisearly detectionmolecular geneticsmolecular diagnosticsbiomarkersgenetics

How a Baby With Classic Galactosemia Was Nearly Missed: When the Test Succeeds but System Fails. American Journal of Medical Genetics Part A (2020)

Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I. International Journal of Neonatal Screening (2020)

early diagnosisbiomarkershealth sciencesbiomarker (medicine)second-tier biomarker

Mucopolysaccharidosis Type I Newborn Screening: Importance of Second Tier Testing for Ethnically Diverse Populations. American Journal of Medical Genetics Part A (2020)

1
2
10 / page